When Will Cardiologists Start Treating Obesity?

Published Date: 14 Nov 2023

Michelle O'Donoghue and Nicholas Marston, cardiologists, talk about the "game changer" trial at AHA that demonstrated how GLP-1 agonist semaglutide decreased the number of CV events in patients with ASCVD who were also overweight or obese.

Read Full News

Latest News

Beyond Hot Flash: Shared Decision-Making in Menopause

A gynecologist and a patient advocate share strategies for alerting patients to the spectrum of menopause symptoms and engaging them in shared decision-making to improve quality of life.

Can Agents Bring Doctors Greater Career Success?

Physician-focused agents have helped doctors navigate job offers, professional growth, media opportunities, and more. Do you need one?

OUD Med Prolongs Ketamine’s Reduction in Suicidal Ideation

A new trial suggests buprenorphine, a medication commonly used to treat opioid use disorder, may help sustain ketamine’s reductions in suicidal ideation.

PA’s Left Off Fed’s New Professional Degree List. Now What?

Physician assistants and nurse practitioners face lower caps on student loans as experts fear the downstream effects.

IUD Workshop Boosts NP Students’ Confidence

An experiential, didactic, and skills-focused workshop for nurse practitioner students can improve their knowledge and comfort with the management of intrauterine devices in primary care.

Rapid Microbe Testing Does Not Cut Antibiotic Prescribing

Rapid microbiological point-of-care testing for respiratory tract infections does not reduce overall same-day antibiotic prescribing in primary care, a recent study shows.

Todays Updates

EMA Backs Breast Cancer SERD After FDA No Vote

The recommendation follows phase 3 data showing longer progression-free survival when patients switched to camizestrant plus a CDK4/6 inhibitor.

Datopotamab Deruxtecan Earns New Breast Cancer Indication

The antibody drug conjugate was approved by the FDA for certain patients with triple-negative breast cancer.

Todays Updates

EMA Backs Breast Cancer SERD After FDA No Vote

The recommendation follows phase 3 data showing longer progression-free survival when patients switched to camizestrant plus a CDK4/6 inhibitor.

Datopotamab Deruxtecan Earns New Breast Cancer Indication

The antibody drug conjugate was approved by the FDA for certain patients with triple-negative breast cancer.

Latest News

A gynecologist and a patient advocate share strategies for alerting patients to the spectrum of menopause symptoms and engaging them in shared decision-making to improve quality of life.

Physician-focused agents have helped doctors navigate job offers, professional growth, media opportunities, and more. Do you need one?

A new trial suggests buprenorphine, a medication commonly used to treat opioid use disorder, may help sustain ketamine’s reductions in suicidal ideation.

Physician assistants and nurse practitioners face lower caps on student loans as experts fear the downstream effects.

An experiential, didactic, and skills-focused workshop for nurse practitioner students can improve their knowledge and comfort with the management of intrauterine devices in primary care.

Rapid microbiological point-of-care testing for respiratory tract infections does not reduce overall same-day antibiotic prescribing in primary care, a recent study shows.

News All Time

Extremely Preterm Birth Tied to Motor Difficulties at Age 12

Children born extremely preterm, even without cerebral palsy or severe neurodevelopmental impairments, show markedly higher rates of motor difficulties at the age of 12 years than peers born at term.

Italian Experts Warn Adolescent Care Gaps Are Growing

Experts say fragmented transitions between pediatric care and primary care may leave adolescents vulnerable during critical developmental years.

Brain-Controlled Hearing System Passes First In-Human Trial

A brain-computer interface that decodes auditory attention in real time improved intelligibility and reduced listening effort in the first human evaluation of the technology.

Women With AxSpA Stop Taking Biologics Earlier Than Men

Women are less likely to stay on TNF and IL-17 inhibitors compared with men, according to findings of a new study.

Ontario Government Expands Access to Fertility Treatment

The Ontario government has invested $100 million to expand access to publicly funded fertility services.

Advance Directives When Suicide Is Involved: Ethicist

Ethicist Art Caplan discusses a recent case involving attempted suicide and advance directives

Despite Advances, Many NSCLC Patients Go Untreated

Treatment rates for metastatic non-small cell lung cancer improved only modestly from 2006 to 2021, despite major advances. However, the study timeline may not reflect current practice.

‘Off-the-Shelf’ CAR T Therapy Shows Early Activity in NHL

Researchers explore the safety and efficacy of an allogeneic CD19-targeted CAR T-cell immunotherapy in patients with relapsed/refractory B-cell non-Hodgkin lymphoma in a phase 1/2 study.

How Menstrual Blood Became a Medical Taboo

Historical theories about menstruation continue to shape medical thinking, women’s education, and diagnostic practices long after scientific evidence challenges these beliefs.

From Dr Google to AI: Are Health Searches Fueling Mistrust?

Online searches and AI advice for symptoms may deepen patient anxiety and mistrust, thereby challenging physicians to build trust during clinical encounters.

Colonoscopy Beyond 75: Are Risks Outweighing Benefits?

Researchers reportsd low colorectal cancer mortality after age 75, even among older adults with previous adenomas detected on colonoscopy.

New Benchmark for Reduced-Intensity Sickle Cell BMT Set

The Hopkins protocol may have solved one of the biggest problems in reduced-intensity sickle cell transplant — graft failure in children — with the added bonus of preserving fertility.

New Data: Perinatal MDD Peaks 2 Weeks After Birth

The rate of major depressive disorder is roughly 6% during pregnancy and 7% during the postpartum period, peaking at about 2 weeks after birth, new research shows.

Mixed Topline Results for Anti-Tau Agent in Phase 2 Trial

Although a new phase 2 study missed its primary endpoint, the anti-tau therapy diranersen reduces tau pathology and shows signs of slowing clinical decline in early AD.

Hormonal Therapies Underused for GSM in Menopause

Structural inequities and lack of information may keep patients from getting the therapies.

Can Common Psychostimulants Ease Cancer-Related Fatigue?

An updated meta-analysis suggests methylphenidate-based psychostimulants may modestly reduce cancer-related fatigue.

Recommended News For You

Should the UK introduce targeted prostate cancer screening? The case for and against

Positive Trials; Malignancies Increasing in Younger Adults; Andre Braugher's Cancer Dx.

PFS in Multiple Myeloma Is Improved by Daratumumab Added to Standard Therapy.

Fear of hair loss might cause some to reject cancer treatment

Telemedicine services linked to reducing excess mortality

How the skin cancer virus outperforms the replication of host cells.

MET Inhibitor Increases Osimertinib Activity in EGFR+ Advanced NSCLC

Recommended Articles For You

Unlocking the Power of Hematocrit: Exploring the Benefits of Blood Cell Counts 

Inside Oncology Trials: From Protocol to Progress in Cancer Research and Care 

Radiation in Oncology: Advances, Applications, and Accessibility 

Unexplained Weight Loss: Revealing Occult Cancers and Paraneoplastic Syndromes 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Breast Cancer Patients Living Longer Post-Medicaid Expansion

2.

Error on the MGUS-Autoimmune Disease Association.

3.

Patients with chronic myeloid leukemia who take nilotinib are at higher risk for diabetes and hyperlipidemia.

4.

The majority of cancer medications that receive expedited approval end up failing confirmatory trials.

5.

Unified Neuro/Psych Residency Program: New Proposal.

1.

Optimizing Melanoma Treatment: Strategies in Diagnosis, Clinical Research, and Physician Training

2.

Hemoglobin C: Understanding its Role in Sickle Cell Disease

3.

Beyond the Human Eye: How AI Is Redefining Brain Cancer Diagnosis Through Advanced Imaging

4.

Understanding Abemaciclib: A Breakthrough Treatment for Breast Cancer 

5.

The Growing Challenge of Haematological Malignancies in Older Adults

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part II

2.

Exploring Potentials of Lorlatinib: The Third Generation ALK-TKI Through CROWN Trial

3.

Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part VII

4.

A Conclusive Discussion on CROWN Trial and the Dawn of a New Era in Frontline Management of ALK+ NSCLC

5.

Efficient Management of First line ALK-rearranged NSCLC - Part VI

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot